Skip to content

Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants

Clinical, Laboratory, and Radiological Characteristics of Urinary Tract Infections in Infants With COVID-19

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05630326
Acronym
ABCUCEOI
Enrollment
5600
Registered
2022-11-29
Start date
2023-03-01
Completion date
2023-07-20
Last updated
2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Insufficiency

Keywords

Chronic Kidney Diseases, Acute Kidney Injury, UTIs in infants, ESBL UTIs, chronic renal failure, UTIs with COVID-19, ESBL organisms with COVID-19

Brief summary

Urinary tract infections (UTIs) in infants and young children are one of the most common bacterial infections, usually febrile illness without source, frequently due to Enterobacteriaceae, mainly Escherichia coli. Multidrug-resistant organisms including extended-spectrum beta-lactamase (ESBL) producing bacteria are becoming more prevalent. Due to the risk factors of ESBL-producing organisms in community-acquired (CA)-UTIs in infants in QATAR and Arab countries are still not studied because of the limited therapeutic options. hence, the importance of this study is to get knowledge about how to decrease the rapidly increasing in ESBL- producing bacteria, in infants, and to use antibiotics in a suitable guideline.so, The aim of this retrospective case-control study is to determine the clinical manifestations, and investigations of urinary tract infections among infants and the association with COVID-19 infection, in pediatric emergency centers at Hamad General Hospital - Qatar. From 1st January 2015 till 1st January 2022.

Detailed description

In this retrospective, case-control study investigators will include all infants (0-1 year) with UTIs who were treated at Hamad General Hospital, pediatric division- PEC Doha, Qatar, using the electronic medical records from 1st January 2015 till January 1st, 2022, diagnosed by a positive urine culture. Investigators will look for the clinical manifestations, radiological and laboratory findings, renal scarring, ESBL-organisms, prevalence, median age, gender, and ethnic background. Participants are divided into two groups: early infancy and late infancy, ESBL UTIs and non-ESBL UTIs, and upper UTIs and lower UTIs. Finally, UTIs ESBL with COVID-19 and without COVID\_19.

Interventions

OTHERcomparing, prevalence

Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.

OTHERassessment

comparing infants with UTIs caused by ESBL organism, or non ESBL organism.

OTHERassociation

comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19

OTHERevaluation

comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19

Sponsors

Hamad Medical Corporation
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 1 Years
Healthy volunteers
No

Inclusion criteria

* All infants with UTIs who had been treated

Exclusion criteria

* Patient with a mixed urine culture.

Design outcomes

Primary

MeasureTime frame
Assessment risk factors , prevalence, and the relation between ESBL UTI and COVID-19 infection of all infants with ESBL- UTIs1year

Countries

Qatar

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026